In the DB phase , @ of @ patients ( @ % with @-month paliperidone palmitate ; @ % with placebo ) had at least @ treatment-emergent adverse event ; those noted more frequently in the group receiving paliperidone palmitate than in the placebo group were headache ( @ % vs @ % ) , weight increased ( @ % vs @ % ) , nasopharyngitis ( @ % vs @ % ) , and akathisia ( @ % vs @ % ) .